Danirixin

N/A

Report date: 2023/10/05 20:00:39
NME

Base Information

Drug NameDanirixin
Drug Alias Name达尼立辛Danirixinum达尼利星DanirixineDanirixina +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 2 antagonists
TargetsC-X-C motif chemokine receptor 2
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveRespiratory Syncytial Virus InfectionsVirus Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveRespiratory Syncytial Virus InfectionsVirus Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG